## **EAACI POSITION PAPER**



Check for updates



# Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement

```
Jean Bousquet<sup>1,2,3,4</sup> | Cezmi A. Akdis<sup>5</sup> | Marek Jutel<sup>6,7</sup> | Claus Bachert<sup>8,9,10,11</sup> | Ludger Klimek<sup>12</sup> | Ioana Agache<sup>13</sup> | Ignacio J. Ansotegui<sup>14</sup> | Anna Bedbrook<sup>4</sup> | Sinthia Bosnic-Anticevich<sup>15,16</sup> | G. Walter Canonica<sup>17,18</sup> | Tomas Chivato<sup>19</sup> | Alvaro A. Cruz<sup>20,21</sup> | Wienczyslawa Czarlewski<sup>22</sup> | Stefano Del Giacco<sup>23</sup> | Hui Du<sup>24</sup> | Joao A. Fonseca<sup>25,26,27,28</sup> | Yadong Gao<sup>29</sup> | Tari Haahtela<sup>30</sup> | Karin Hoffmann-Sommergruber<sup>31</sup> | Juan-Carlos Ivancevich<sup>32</sup> | Nikolaï Khaltaev<sup>33</sup> | Edward F. Knol<sup>34</sup> | Piotr Kuna<sup>35</sup> | Desiree Larenas-Linnemann<sup>36</sup> | Joaquim Mullol<sup>37,38</sup> | Robert Naclerio<sup>39</sup> | Ken Ohta<sup>40</sup> | Yoshitaka Okamoto<sup>41</sup> | Liam O'Mahony<sup>42</sup> | Gabrielle L. Onorato<sup>4</sup> | Nikos G. Papadopoulos<sup>43,44</sup> | Oliver Pfaar<sup>45</sup> | Boleslaw Samolinski<sup>46</sup> | Jürgen Schwarze<sup>47</sup> | Sanna Toppila-Salmi<sup>30</sup> | Maria-Teresa Ventura<sup>48</sup> | Arunas Valiulis<sup>49,50</sup> | Arzu Yorgancioglu<sup>51</sup> | Torsten Zuberbier<sup>52,53</sup> | Ruby Pawankar<sup>54</sup> | the ARIA-MASK Study Group*
```

Bousquet, Akdis and Jutel participated equally to the paper.

Bousquet, Bachert, Bedbrook, Bosnic-Anticevich, Canonica, Cruz, Czarlewski, Fonseca, Haahtela, Ivancevich, Kuna, Larenas-Linnemann, Mullol, Naclerio, Ohta, Okamoto, Papadopoulos, Pawankar, Pfaar, Samolinski, Toppila-Salmi, Valiulis, Yorgancioglu and Zuberbier are members of the ARIA and MASK boards.

Jutel, Klimek, Agache, Chivato, Sommergruber, Knol, O'Mahony and Schwarze are members of the EAACI board of officers.

§The ARIA-MASK Study Group members are shown in Appendix 1.

© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.



<sup>&</sup>lt;sup>1</sup>Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany

<sup>&</sup>lt;sup>2</sup>Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin, Germany

<sup>&</sup>lt;sup>3</sup>University Hospital Montpellier, Montpellier, France

<sup>&</sup>lt;sup>4</sup>MACVIA-France, Montpellier, France

<sup>&</sup>lt;sup>5</sup>Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland

<sup>&</sup>lt;sup>6</sup>Department of Clinical Immunology, Wrocław Medical University, Wroclaw, Poland

<sup>&</sup>lt;sup>7</sup>ALL-MED Medical Research Institute, Wroclaw, Poland

<sup>&</sup>lt;sup>8</sup>Upper Airways Research Laboratory, ENT Dept, Ghent University Hospital, Ghent, Belgium

<sup>&</sup>lt;sup>9</sup>Sun Yat-sen University, International Airway Research Center, Ghent University Hospital, First Affiliated Hospital, Guangzhou, China

 $<sup>^{\</sup>rm 10}{\rm Division}$  of ENT Diseases, CLINTEC, Karolinska Institutet, Stockholm, Sweden

<sup>&</sup>lt;sup>11</sup>Department of ENT Diseases, Karolinska University Hospital, Stockholm, Sweden

<sup>&</sup>lt;sup>12</sup>Center for Rhinology and Allergology, Wiesbaden, Germany

<sup>&</sup>lt;sup>13</sup>Transylvania University Brasov, Brasov, Romania

 $<sup>^{14}\</sup>mbox{Department}$  of Allergy and Immunology, Hospital Quirónsalud Bizkaia, Erandio, Spain

 $<sup>^{15}</sup>$ Woolcock Institute of Medical Research, University of Sydney, Sydney, NSW, Australia

<sup>&</sup>lt;sup>16</sup>Woolcock Emphysema Centre and Sydney Local Health District, Glebe, NSW, Australia

<sup>&</sup>lt;sup>17</sup>Personalized Medicine, Asthma and Allergy - Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy

<sup>&</sup>lt;sup>18</sup>Department of Biomedical Sciences - Humanitas University -, Pieve Emanuele, Milan,, Italy

 $<sup>^{19}\</sup>mbox{School}$  of Medicine, University CEU San Pablo, Madrid, Spain

- <sup>20</sup>ProAR Nucleo de Excelencia em Asma, Federal University of Bahia, Salvador, Brasil
- <sup>21</sup>WHO GARD Planning Group, Montpellier, Brazil
- <sup>22</sup>Medical Consulting Czarlewski, Levallois, and MASK-air, Montpellier, France
- <sup>23</sup>Department of Medical Sciences and Public Health and Unit of Allergy and Clinical Immunology, University Hospital "Duilio Casula", University of Cagliari, Cagliari, Italy
- <sup>24</sup>Department of Respiratory Medicine, Wuhan Children's Hospital, Tongji Medical College, Huazhong, University of Science and Technology, Wuhan, Hubei, China
- <sup>25</sup>Center for Research in Health Technologies and Information Systems- CINTESIS, Universidade do Porto, Porto, Portugal
- <sup>26</sup>Allergy Unit, Instituto CUF Porto e Hospital CUF Porto, Porto, Portugal
- <sup>27</sup>Health Information and Decision Sciences Department CIDES, Faculdade de Medicina, Universidade do Porto, Porto, Portugal
- <sup>28</sup>Faculdade de Medicina da Universidade do Porto, Porto, Portugal
- <sup>29</sup>Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
- <sup>30</sup>Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland
- <sup>31</sup>Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria
- <sup>32</sup>Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina
- 33GARD Chairman, Geneva, Switzerland
- <sup>34</sup>Departments of Immunology and Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands
- <sup>35</sup>Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland
- <sup>36</sup>Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico
- <sup>37</sup>Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, Barcelona, Spain
- 38 Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Spain
- <sup>39</sup>Johns Hopkins School of Medicine, Baltimore, MD, USA
- <sup>40</sup>National Hospital Organization, Tokyo National Hospital, Tokyo, Japan
- <sup>41</sup>Department of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan
- <sup>42</sup>Departments of Medicine and Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland
- <sup>43</sup>Division of Infection, Immunity & Respiratory Medicine, Royal Manchester Children's Hospital, University of Manchester, Manchester, UK
- <sup>44</sup>Allergy Dpt, 2nd Pediatric Clinic, University of Athens, Athens, Greece
- <sup>45</sup>Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Germany
- <sup>46</sup>Department of Prevention of Envinronmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland
- <sup>47</sup>Centre for Inflammation Research, Child Life and Health, The University of Edinburgh, Edinburgh, UK
- <sup>48</sup>Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy
- <sup>49</sup>Vilnius University Faculty of Medicine, Institute of Clinical Medicine & Institute of Health Sciences, Vilnius, Lithuania
- <sup>50</sup>European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium
- <sup>51</sup>Celal Bayar University Department of Pulmonology, Manisa, Turkey
- <sup>52</sup>Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Uniersität zu Berlin, Berlin, Germany
- <sup>53</sup>Berlin Institute of Health, Comprehensive Allergy-Centre, Department of Dermatology and Allergy, Member of GA<sup>2</sup>LEN, Berlin, Germany
- <sup>54</sup>Department of Pediatrics, Nippon Medical School, Tokyo, Japan

Correspondence: Jean Bousquet, CHU Arnaud de Villeneuve, 371 Avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France. Email: jean.bousquet@orange.fr

A novel strain of human coronaviruses, named by the International Committee on Taxonomy of Viruses (ICTV)<sup>1</sup> as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged and caused an infectious disease. This disease has recently been referred to by the World Health Organisation (WHO) as the "coronavirus disease 2019" (COVID-19). Since the first report of this disease in December 2019 in Wuhan, China,<sup>2,3</sup> COVID-19 has aggressively spread across the globe. WHO declared it a pandemic on March 11.

COVID-19 presents with many different clinical manifestations, ranging from asymptomatic cases to mild and severe disease, with or without pneumonia.<sup>4</sup> Patients with common allergic conditions do not develop additional distinct symptoms and do not seem to be at an increased risk of severe disease. Allergic children show a

mild course, like other children.<sup>5</sup> COVID-19 cases with pre-existing COPD, or complicated by secondary bacterial pneumonia, are more severe, and this may be due to a complex immune pathogenesis.

Whether systemic corticosteroids have a deleterious effect on COVID-19 infection is still a matter of discussion. Clinical evidence does not support corticosteroid treatment for SARS-CoV-2 pneumonia.<sup>6</sup> Moreover, corticosteroid therapy in patients with MERS (Middle East respiratory syndrome) was not associated with a difference in mortality after adjustment for time-varying confounders but was associated with delayed MERS coronavirus RNA clearance.<sup>7</sup> In accordance with current WHO guidance,<sup>8</sup> it has been proposed that corticosteroids should not be used for SARS-CoV-2 -induced lung injury or shock, except in the setting of a clinical trial. However,

a team of front-line physicians from China had a different perspective. Given the inconclusive evidence and urgent clinical demand, physicians from the Chinese Thoracic Society have developed an expert consensus statement on the use of corticosteroids in SARS-CoV-2 pneumonia that may allow the restricted use of low doses of corticosteroids for a short duration. On the use of low doses of corticosteroids for a short duration.

Concerning inhaled corticosteroids in asthma, the Global Initiative for Asthma (GINA) recently stated the following (https://ginasthma.org/recommendations-for-inhaled-asthma-controller-medications/): "Some sources have suggested that "corticosteroids" should be avoided during the for SARS-CoV-2 epidemic. This advice is about the use of oral corticosteroids unless there is a clear indication for their use. However, patients with asthma should not stop their prescribed inhaled corticosteroid controller medication (or prescribed oral corticosteroids). Stopping inhaled corticosteroids often leads to potentially dangerous worsening of asthma, and avoiding oral corticosteroids during severe asthma attacks may have serious consequences. Long-term oral corticosteroids may sometimes be required to treat severe asthma, and it may be dangerous to stop them suddenly. Always discuss with your doctor or nurse before stopping

any asthma medication. Keep taking your inhaled asthma controller medication, and if your asthma gets worse, follow the instructions on your asthma action plan for how to change your asthma medications and when to seek medical help."

Some scientific societies have made recommendations for anosmia and have proposed the use of intranasal corticosteroids. However, the French Agency (Direction Générale de la Santé) has contraindicated their use in anosmia and ageusia without nasal obstruction. They have extended the contraindication to saline washing since this could promote viral dissemination.

ARIA and EAACI followed the example of the Dutch ENT Society and sent a questionnaire to all ARIA members regarding the recommendations for allergic rhinitis and anosmia. ARIA and EAACI are proposing a joint statement following the results of the questionnaire.

#### 1 | Anecdotal evidence

In the Wuhan Children's hospital, there were about 40 paediatric COVID-19 cases with AR. Among these cases, approximately one

**TABLE 1** Results of the questionnaire

		Agree	Somewhat disagree	Completely disagree	No answer
1	Currently, nasal corticosteroid spray can be continued in the hay fever season.	175 (91.6%)	4 (2.2%)	3 (1.5%)	9 (4.7%)
2	Stopping local nasal corticoid spray is not advised: suppression of the immune system has not been proven, and more sneezing after stopping means more spreading of the Coronavirus.	173 (90.6%)	4 (2.2%)	3 (1.5%)	11 (5.8%)
3	Prescribing local nasal spray against anosmia due to Corona infection does not make sense.	100 (51.6%)	3 (1.5%)	0	88 (47.5%)




FIGURE 1 List of countries with at least one answer to the questionnaire [Color figure can be viewed at wileyonlinelibrary.com]

third used intranasal steroids regularly as before, the other two thirds did not. It was observed in these two patient groups that there was no difference in the severity and prognosis of COVID-19 and that all of them recovered well. (Personal communication Yadong Gao and Hui Du, Unpublished data).

## 2 | Questionnaire

A Delphi process was initiated by Anna Bedbrook who sent the three questions proposed by the Dutch ENT Society to the entire ARIA database (509 members, 84 countries), asking members to agree, somewhat disagree or completely disagree. After 48 hours, 209 replies were received from 61 countries (Table 1 and Figure 1).

#### 3 | Recommendations

With the current knowledge, in patients with COVID-19 infection, intranasal corticosteroids (including spray) can be continued in allergic rhinitis at the recommended dose.

Stopping local intranasal corticosteroids is not advised. Suppression of the immune system has not been proven and more sneezing after stopping means more spreading of the Coronavirus.

These recommendations are conditional since there is a paucity of data and they should be revised regularly with new knowledge.

## ORCID

Cezmi A. Akdis https://orcid.org/0000-0001-8020-019X

Claus Bachert https://orcid.org/0000-0003-4742-1665

loana Agache https://orcid.org/0000-0001-7994-364X

Alvaro A. Cruz https://orcid.org/0000-0002-7403-3871

Tari Haahtela https://orcid.org/0000-0003-4757-2156

Ken Ohta https://orcid.org/0000-0001-9734-4579

Liam O'Mahony https://orcid.org/0000-0003-4705-3583

Nikos G. Papadopoulos https://orcid.

org/0000-0002-4448-3468

Oliver Pfaar https://orcid.org/0000-0003-4374-9639

Torsten Zuberbier https://orcid.org/0000-0002-1466-8875

#### **REFERENCES**

- Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020. https://doi.org/10.1038/s4156 4-020-0695-z [Epub ahead of print].
- Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8): 727-733.
- Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020.

- Dong X, Cao YY, Lu XX, et al. Eleven Faces of Coronavirus Disease 2019. Allergy 2020;75:1699-1709. https://doi.org/10.1111/ all.14289
- Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020;75:1730-1741. https://doi.org/10.1111/all.14238
- Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. *Lancet* 2020;395(10223):473-475.
- Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med. 2018;197(6):757-767.
- Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. 2020. https:// www.who.int/publications-detail/clinical-management-of-sever e-acute-respiratory-infection-when-novelcoronavirus-(ncov)-infection-is-suspected.
- Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. *Lancet*. 2020;395(10225):683-684.
- 10. Zhao JP, Hu Y, Du RH, et al. Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia. *Zhonghua Jie He He Hu Xi Za Zhi*. 2020;43(3):183-184.
- INF-16 Information sur les formes cliniques atypiques de COVID-19. DGS. 2020. dgs-urgent@dgs-urgentsantegouvfr.

#### **APPENDIX 1**

# ARIA- MASK study group

Amir H Abdul Latiff, Mübeccel Akdis, Mona Al-Ahmad, Emilio Alvarez Cuesta, Hasan Arshad, Maria Cristina Artesani, Zeinab Awad, Mostafa Badr Eldin, Sergio Barba, Cristina Barbara, Eric D Bateman, Bianca Beghe, Elisabeth Bel, Karl-Christian Bergmann, Elena Camelia Berghea, David Bernstein, Leif Bjermer, Attilio Boner, Sergio Bonini, Isabelle Bosse, Jacques Bouchard, Louis-Philippe Boulet, Fulvio Braido, Christopher Brightling, Roland Buhl, Carmen Bunu, Andrew Bush, William W Busse, Fernando Caballero-Fonseca, Davide Caimmi, Silvia Caimmi, Paulo Camargos, Vicky Cardona, Kai-Hakon Carlsen, Warner Carr, Pedro Carreiro-Martins, Thomas Casale, Lorenzo Cecchi, Niels H Chavannes, Alfonso Cepeda, Ekaterine Chkhartishvili, George Christoff, Derek K Chu, Cemal Cingi, Giorgio Ciprandi, Ieva Cirule, Jaime Correia de Sousa, Maria del Carmen Costa Dominguez, André Coste, Linda Cox, Adnan Custovic, Ulf Darsow, Frédéric de Blay, Diana Deleanu, Pascal Demoly, Philippe Devillier, Alain Didier, Ratko Djukanovic, Maria Do Ceu Teixeira, Dejan Dokic, Ruta Dubakiene, Stephen Durham, Patrik Eklund, Yehia El-Gamal, Regina Emuzyte, Julia Esser-von-Bieren, Alessandro Fiocchi, Wytske J Fokkens, Mina Gaga, José Luis Gálvez Romero, Bilun Gemicioglu, Sonya Genova, José Gereda, Maximiliano Gomez, Maia Gotua, Ineta Grisle, Marta Guidacci, Maria Antonieta Guzmán, Adnan Hejjaoui, Elham Hossny, Jonathan O Hourihane, Martin Hrubiško, Yunuen Huerta Villalobos, Guido Iaccarino, Carla Irani, Zhanat Ispayeva, Edgardo Jares, Ewa Jassem, Erika Jensen-Jarolim, Sebastian Johnston, Guy Joos, Ki-Suck Jung, Jocelyne Just, Igor Kaidashev, Omer Kalayci, Fuat Kalyoncu, Przemyslaw Kardas, Jussi Karjalainen, Jorg Kleine-Tebbe, Gerard Koppelman, Marek L Kowalski, Mikael Kuitunen, Violeta Kvedariene, Susanne Lau, Lan Le, Marcus Lessa, Michael Levin, Jing Li, Philip Lieberman, Brian Lipworth, Karin C Lodrup Carlsen, Bassam Mahboub, Mika Makela, Hans-Jorgen Malling, Gailen Marshall, Pedro Carreiro-Martins, Mohammad Masjedi, Juan José Matta, Cem Meço, Erik Melén, Eli O Meltzer, Hans Merk, Jean-Pierre Michel, Florin Mihaltan, Neven Miculinic, Branislava Milenkovic, Yousser Mohammad, Mathieu Molimard, Mario Morais-Almeida, Ralph Mösges, Lars Münter, Antonella Muraro, Tihomir Mustakov, Alla Nakonechna, Leyla Namazova-Baranova, Kristof Nekam, Laurent Nicod, Robyn O'Hehir, Kimihiro Okubo, Brian Oliver, Pier Luigi Paggiaro, Isabella Pali-Schöll, Petr Panzner, Hae-Sim Park, Ana Pereira, Bernard Pigearias, Constantinos Pitsios, Davor Plavec, Wolfgang Pohl, Todor Popov, Fabienne Portejoie, Paul Potter, Lars Poulsen, Emmanuel Prokopakis, Klaus Rabe, Marysia Recto, Janet Rimmer, Jose Angelo Rizzo, Graham

Roberts, Nicolas Roche, Antonino Romano, Jose Rosado-Pinto, Nelson Rosario, Lanny Rosenwasser, Philip Rouadi, Dermot Ryan, Mario Sanchez-Borges, Joaquin Sastre-Dominguez, Glenis Scadding, Elie Serrano, Nikolaos Siafakas, Estelle F Simons, Juan-Carlos Sisul, Dirceu Solé, Talant Sooronbaev, Manuel Soto-Martinez, Manuel Soto-Quiros, Cristiana Stellato, Rafael Stelmach, Timo Strandberg, Charlotte Suppli Ulrik, Carel Thijs, Peter-Valentin Tomazic, Massimo Triggiani, Ioanna Tsiligianni, Marilyn Urrutia Pereira, Marylin Valentin Rostan, Erkka Valovirta, Eric Van Ganse, Marianne van Hage, Olivier Vandenplas, Petra Vidgren, Martin Wagenmann, Dana Wallace, De Yun Wang, Susan Waserman, Magnus Wickman, Dennis Williams, Barbara Yawn, Osman B Yusuf, Mario Zernotti, Mihaela Zidarn.